Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 103Carcinoma, Renal Cell 30Urinary Bladder Neoplasms 22Breast Neoplasms 20Lung Neoplasms 10Carcinoma, Transitional Cell 10Neoplasms 8Melanoma 8Kidney Neoplasms 8Neoplasm Metastasis 7Colonic Neoplasms 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Metastatic Castration-resistant Prostate Cancer 6Sarcoma 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Brain Neoplasms 4Diabetes Mellitus 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Urologic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Rectal Neoplasms 2Prostatic Hyperplasia 2Prostate Cancer Castration-resistant Prostate Cancer 2Osteosarcoma 2

Interventions

sacituzumab govitecan 1pembrolizumab 1erdafitinib 1enfortumab vedotin 1avelumab 1Vinblastine 1Paclitaxel 1Nivolumab 1Methotrexate 1Gemcitabine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Muscle Invasive Bladder Urothelial Carcinoma × Genitourinary × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡